CLL-MRD (Minimal Residual Disease)

CPT 88184(1), 88185(11), 88188(1) (units of 88185 vary depending on the number of antibodies tested)

SLL; Chronic Leukemia/Lymphoma; Flow Cytometry; Lymphoma

Test Details

Cancer Type

Chronic lymphocytic leukemia (CLL), Hematologic malignancies, Leukemia

Technology Used


Turnaround Time

1-3 days


CLL-MRD testing utilizes a 12-antibody flow cytometry panel in concert with a sequential gating strategy to isolate pure CLL B-cells from normal B-cells and regenerating cells. This process allows for the differentiation of 1 CLL cell in 10,000 normal B-cells and provides a quantitative measurement of the MRD status of patients with CLL who are undergoing therapy. Patients who achieve CLL-MRD-negative status have improved overall and progression-free survival. This test is not suitable for making primary diagnosis or monitoring untreated CLL patients with a high tumor load.


There must be a minimum of 5 million cells in the specimen submitted to perform the test (10 million cells preferred).


Flow Cytometry

Specimen Requirements

Information on collection, storage, and volume


Whole blood or bone marrow


10 mL whole blood; 2 mL bone marrow aspirate


Green-top (sodium heparin) tube (preferred) or lavender-top (EDTA)

Storage Instructions

Maintain specimen at room temperature.

Causes for Rejection

Hemolysis; specimen clotted; specimen frozen; specimen in formalin or other fixative; blood more than 72 hours old; bone marrow aspirates more than five days old; bags or bottles of body fluid or bronchial washing; tissue in formalin or other fixative; contaminated transport medium


All specimens should be shipped to Labcorp Oncology on the day of excision. Delay in shipping may compromise cell viability and results.